NO954175L - Anvendelse av vWF-inneholdende konsentrater som kombinasjonsterapi ved antitrombotika og fibrinolytika terapi - Google Patents

Anvendelse av vWF-inneholdende konsentrater som kombinasjonsterapi ved antitrombotika og fibrinolytika terapi

Info

Publication number
NO954175L
NO954175L NO954175A NO954175A NO954175L NO 954175 L NO954175 L NO 954175L NO 954175 A NO954175 A NO 954175A NO 954175 A NO954175 A NO 954175A NO 954175 L NO954175 L NO 954175L
Authority
NO
Norway
Prior art keywords
therapy
vwf
antithrombotic
fibrinolytic
containing concentrates
Prior art date
Application number
NO954175A
Other languages
English (en)
Norwegian (no)
Other versions
NO954175D0 (no
Inventor
Martin Reers
Gerhard Dickneite
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of NO954175D0 publication Critical patent/NO954175D0/no
Publication of NO954175L publication Critical patent/NO954175L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO954175A 1994-10-20 1995-10-19 Anvendelse av vWF-inneholdende konsentrater som kombinasjonsterapi ved antitrombotika og fibrinolytika terapi NO954175L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4437544A DE4437544A1 (de) 1994-10-20 1994-10-20 Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika

Publications (2)

Publication Number Publication Date
NO954175D0 NO954175D0 (no) 1995-10-19
NO954175L true NO954175L (no) 1996-04-22

Family

ID=6531287

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954175A NO954175L (no) 1994-10-20 1995-10-19 Anvendelse av vWF-inneholdende konsentrater som kombinasjonsterapi ved antitrombotika og fibrinolytika terapi

Country Status (20)

Country Link
US (1) US5571784A (fi)
EP (1) EP0713881A3 (fi)
JP (1) JPH08208504A (fi)
KR (1) KR960013383A (fi)
CN (1) CN1128168A (fi)
AU (1) AU708670B2 (fi)
CA (1) CA2160975A1 (fi)
CZ (1) CZ287878B6 (fi)
DE (1) DE4437544A1 (fi)
FI (1) FI954964A (fi)
HR (1) HRP950525A2 (fi)
HU (1) HU219595B (fi)
IL (1) IL115652A (fi)
NO (1) NO954175L (fi)
NZ (1) NZ280274A (fi)
PL (1) PL183182B1 (fi)
SK (1) SK129695A3 (fi)
TW (1) TW398977B (fi)
UY (1) UY24063A1 (fi)
ZA (1) ZA958838B (fi)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
AT405485B (de) * 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
AT409335B (de) * 1998-11-10 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
CN102770449B (zh) * 2010-02-16 2016-02-24 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
TWI580423B (zh) * 2013-12-24 2017-05-01 財團法人工業技術研究院 緩解或治療痛風之醫藥組合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4774323A (en) * 1987-06-29 1988-09-27 Rorer Pharmaceutical Corporation Purification of von Willebrand Factor solutions using gel permeation chromatography
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
GB8823480D0 (en) * 1988-10-06 1988-11-16 Ciba Geigy Ag Antidote
US5204323B1 (en) 1988-10-06 1995-07-18 Ciba Geigy Corp Hirudin antidotal compositions and methods
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
DE4115453A1 (de) * 1991-05-11 1992-11-12 Knoll Ag Neue wirkstoffkombination
US5366869A (en) * 1991-11-08 1994-11-22 Sheldon Goldstein Multiple coagulation test device and method
DE4203965A1 (de) * 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
IL109383A0 (en) * 1993-04-23 1994-07-31 Bio Technology General Corp Method for enhancing thrombolysis

Also Published As

Publication number Publication date
SK129695A3 (en) 1996-10-02
NO954175D0 (no) 1995-10-19
CN1128168A (zh) 1996-08-07
PL183182B1 (pl) 2002-06-28
NZ280274A (en) 1997-01-29
FI954964A0 (fi) 1995-10-18
UY24063A1 (es) 1995-10-24
US5571784A (en) 1996-11-05
TW398977B (en) 2000-07-21
AU3430495A (en) 1996-05-02
CZ287878B6 (cs) 2001-03-14
HU9503031D0 (en) 1995-12-28
ZA958838B (en) 1996-05-13
HRP950525A2 (en) 1997-04-30
EP0713881A2 (de) 1996-05-29
CZ271995A3 (en) 1996-05-15
HUT73762A (en) 1996-09-30
IL115652A0 (en) 1996-01-19
CA2160975A1 (en) 1996-04-21
DE4437544A1 (de) 1996-04-25
KR960013383A (ko) 1996-05-22
EP0713881A3 (de) 1996-08-21
FI954964A (fi) 1996-04-21
HU219595B (hu) 2001-05-28
IL115652A (en) 2000-08-31
PL311031A1 (en) 1996-04-29
AU708670B2 (en) 1999-08-12
JPH08208504A (ja) 1996-08-13

Similar Documents

Publication Publication Date Title
WO2001049236A3 (en) Method and system for treating cardiac arrest
ATE153856T1 (de) Zusammensetzung zur stimulierung des immunsystems
Shawl et al. Emergency cardiopulmonary bypass support in patients with cardiac arrest in the catheterization laboratory
EP1019072A4 (en) ASSISTANCE PROCESS FOR DIFFERENTIAL DIAGNOSIS AND TREATMENT OF AUTISM SYNDROME
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
IL76119A0 (en) Initiating reperfusion treatment when heart attack symptoms are present
DE69722401D1 (de) Kombinationen von vasopressin und adrenergischen wirkstoffen zur behandlung des plötzlichen herztods
EP0246715A3 (en) Apparatus for the safe delivery of a beneficial agent to a patient
FI19991893A (fi) Säädellysti budesonidia vapauttava oraalisesti annettava koostumus ja budesonidin käyttö
NO954175L (no) Anvendelse av vWF-inneholdende konsentrater som kombinasjonsterapi ved antitrombotika og fibrinolytika terapi
IE790951L (en) Carnitine solution
WO2000064456A3 (en) Substitution infusion fluid and citrate anticoagulation
ATE97813T1 (de) Mittel zur kontrolle von thrombenbildungen.
ATE307634T1 (de) Photopherese-behandlung von hcv-infektionen
BR9713653B1 (pt) composiÇço farmacÊutica, mÉtodo para preparar uma composiÇço farmacÊutica, e, uso de pirofosfato fÉrrico.
Yokoyama et al. Comparative study of biocompatibility between the open circuit and closed circuit in cardiopulmonary bypass.
MD990258A (en) Method of treatment of the acute viral hepatitis B
Teoh et al. Blood conservation with membrane oxygenators and dipyridamole
DE69227042D1 (de) Verfahren und zusammensetzungen zur verminderung von blutverlust
Takanashi et al. Reduction of myocardial infarct size in swine: a comparative study of intraaortic balloon pumping and transapical left ventricular bypass
DE69943240D1 (de) Verwendung von HGF für die Behandlung von ischämischen Erkrankungen der Extremitäten
EP0397211A3 (en) Percutaneous administration of 3'-azide-3'-deoxythymidine
DE3650368D1 (de) Verwendung von Depogen zur Behandlung von eingeschränktem Blutkreislauf.
JPS57116017A (en) Antithrombogenetic or anticoagulative agent
Henley et al. Acute haemodilution in surgery for burns: a preliminary report

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application